Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer

NCT04343885 is registered in ClinicalTrials.gov with Peter MacCallum Cancer Centre, Australia as lead sponsor.

NCT NCT04343885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04343885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer
Lead sponsor
Peter MacCallum Cancer Centre, Australia
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 21, 2020
Completion date
March 31, 2026
Enrollment
130 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone naive prostate cancer